Navigation Links
Ulcer Preventative May Raise Pneumonia Risks
Date:9/18/2009

Trend seen in hospital patients also leads to higher costs, study finds

FRIDAY, Sept. 18 (HealthDay News) -- A popular stomach acid reducer greatly increases the risk of pneumonia in certain critically ill hospital patients, a new study has found.

Researchers at Wake Forest University School of Medicine in North Carolina analyzed the charts of 834 cardiothoracic surgery patients on breathing machines who were given stomach acid reducers to prevent stress ulcers. The patients were given either ranitidine (Zantac) or pantoprazole (Protonix). Both drugs reduce stomach acid, but pantoprazole is more powerful and is the drug of choice in many hospitals.

However, the study found that people given pantoprazole were three times more likely to develop hospital-acquired pneumonia than those given ranitidine. The findings were published recently in Chest.

"We conducted this study, in part, because we thought we were seeing more pneumonias than we were used to having," Marc G. Reichert, pharmacy coordinator for surgery at Wake Forest University Baptist Medical Center and a co-author of the study, said in a university news release.

Hospital-acquired pneumonia -- the leading cause of infection-related deaths in critically ill patients -- increases hospital stays by an average of seven to nine days, adds to the overall costs of care and raises the risk for other complications.

People on breathing machines sometimes develop pneumonia when stomach secretions reflux into the lungs.

More information

The U.S. National Library of Medicine has more on hospital-acquired pneumonia.



-- Robert Preidt



SOURCE: Wake Forest University School of Medicine, news release, Sept. 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
2. New therapeutic targets in the treatment of ulcerative colitis
3. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
4. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
5. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
6. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
7. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
8. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
9. Novel toxin receptor discovered for ulcer-causing stomach pathogen
10. Medlines Pressure Ulcer Prevention Program Addresses New CMS Deadline of October 1, 2008
11. Wound Care Education Institute to Partner with Wisconsin Organizations to Improve Pressure Ulcer Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ulcer Preventative May Raise  Pneumonia Risks
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: